Aditx Therapeutics Inc Forecast, price target & analysts
Aditx Therapeutics Inc Target price 2024 - Analyst rating & recommendation
Aditx Therapeutics Inc Classifications & Recommendation:
Aditx Therapeutics Inc Price Target
| Target Price | $2,440.00 |
| Price | $0.40 |
| Potential |
609,900.00%
register free of charge
|
| Number of Estimates | 1 |
|
1 Analyst has issued a Aditx Therapeutics Inc price target 2025.
The average Aditx Therapeutics Inc target price is $2,440.00.
This is
609,900.00%
register free of charge
|
|
| A rating was issued by 1 analysts: 1 Analysts recommend Aditx Therapeutics Inc to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Aditx Therapeutics Inc stock has an average upside potential 2025 of
609,900.00%
register free of charge
|
Sales and Margin forecast 2024, 2025 & 2026
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.65 | 1.48 |
| 30.11% | 126.92% | |
| Net Margin | -352,745.17% | -12,312.37% |
| 939.41% | 96.51% |
1 Analyst has issued a sales forecast Aditx Therapeutics Inc 2024 . The average Aditx Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
Revenue Estimates
| 2023 | $650k | 30.11% |
|---|---|---|
| 2024 |
$1.5m
126.92%
Unlock
|
|
The average Aditx Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2023 | $-2.3b | 626.47% |
|---|---|---|
| 2024 |
$-182m
92.08%
Unlock
|
|
Net Margin
| 2023 | -352,745.17% | 939.41% |
|---|---|---|
| 2024 |
-12,312.37%
96.51%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4,326.12 | -91.26 |
| 626.47% | 97.89% | |
| P/E | 0.00 | |
| EV/Sales | 6.31 |
The average Aditx Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2023 | $-4,326.12 | 626.47% |
|---|---|---|
| 2024 |
$-91.26
97.89%
Unlock
|
|
P/E ratio
| Current | 0.00 | 100.00% |
|---|
Based on analysts' sales estimates for 2024, the Aditx Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 62.71 | 756.69% |
|---|---|---|
| 2024 |
6.31
89.93%
Unlock
|
|
P/S ratio
| Current | 16.67 | 1,711.60% |
|---|---|---|
| 2024 |
1.07
93.57%
Unlock
|
|
Aditx Therapeutics Inc...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
